NCT04838652View on ClinicalTrials.gov

Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 5, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2028

Conditions

Classical Hodgkin Lymphoma

Interventions

DRUG

Pembrolizumab plus Chemotherapy (ICE or DHAP)

Pembrolizumab (200mg) alone or in combination with ICE (or DHAP in case of PET positive findings after P-ICE) will be admistered. 6 additional courses of pembrolizumab will be administered after the completion P-ICE or P-DHAP

Trial Locations (1)

Unknown

RECRUITING

1st Department of Medicine, Cologne University Hospital, Cologne

All Listed Sponsors

lead

University of Cologne

OTHER